These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30133998)

  • 61. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
    Dressler C; Rosumeck S; Werner RN; van der Kraaij G; van Lumig P; Wakkee M; Spuls P; Nast A
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1964-1977. PubMed ID: 28944515
    [No Abstract]   [Full Text] [Related]  

  • 62. Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis.
    Quach OL; Hsu S
    JAMA Dermatol; 2016 Apr; 152(4):486-7. PubMed ID: 26720159
    [No Abstract]   [Full Text] [Related]  

  • 63. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
    van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
    Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
    [No Abstract]   [Full Text] [Related]  

  • 64. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S; Nakano A; Dakeshita H; Li J; Betts KA; Guerin A
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.
    van den Reek JMPA; van Vugt LJ; van Doorn MBA; van der Kraaij GE; de Kort WJA; Lucker GPH; Horvath B; Njoo MD; Bovenschen HJ; Ossenkoppele PM; De Bruin-Weller MS; de Groot M; Mommers R; Prevoo RLMA; van de Kerkhof PCM; Spuls PI; Kievit W; de Jong EMGJ
    Acta Derm Venereol; 2018 Jul; 98(7):648-654. PubMed ID: 29405245
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis?
    Ingram JR; Anstey AV; Piguet V
    Br J Dermatol; 2012 Oct; 167(4):949-51. PubMed ID: 22486276
    [No Abstract]   [Full Text] [Related]  

  • 67. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Infliximab reduces oxidative stress in ankylosing spondylitis.
    Feijóo M; Túnez I; Tasset I; Montilla P; Ruiz A; Collantes E
    Clin Exp Rheumatol; 2009; 27(1):167-8; author reply 168. PubMed ID: 19327250
    [No Abstract]   [Full Text] [Related]  

  • 70. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
    Yip L; Harrison S; Foley P
    Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Depression? It's the Disease NOT the Drug.
    Kircik LH
    J Drugs Dermatol; 2018 Aug; 17(8):s28. PubMed ID: 30124736
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use.
    Beecker J; Joo J
    J Cutan Med Surg; 2018; 22(1):86-88. PubMed ID: 28735569
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment.
    Bacchetti T; Campanati A; Ferretti G; Simonetti O; Liberati G; Offidani AM
    Br J Dermatol; 2013 May; 168(5):984-9. PubMed ID: 23614561
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical experience with infliximab biosimilar in psoriasis.
    Ricceri F; Pescitelli L; Lazzeri L; Prignano F
    Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
    [No Abstract]   [Full Text] [Related]  

  • 77. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
    Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
    J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
    Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
    Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
    Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
    J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Our experience with infliximab in reclacitrant cases of psoriasis].
    Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.